Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Toronto

$27,000.00

Development of Novel Histone Deacetylase Inhibitors for Treatment of Diffuse Intrinsic Pontine Glioma

FY 2025-26

Summary
Diffuse Intrinsic Pontine Glioma (DIPG) is a highly aggressive pediatric brainstem tumor that affects about 30 Canadian children per year. DIPG tumors cannot be surgically removed as they affect the pons region of the brainstem, which is responsible for many vital functions like heart rate and breathing rate. There are currently no viable chemotherapeutics for DIPG as all drugs that have shown promise in vitro have poor blood-brain barrier (BBB) permeability and off-target toxicity. As such, DIPG has no effective treatment and is universally fatal. The proposed research aims to develop a medicinal chemistry approach to synthesize novel anti-DIPG pharmaceuticals. Current research has shown that DIPG is driven by mutations in histone proteins that cause profound changes in gene transcription patterns, including inhibition of tumor suppressor genes and relative overexpression of oncogenes. This dysregulation of gene expression can be reversed by inhibiting histone deacetylase enzymes (HDACs), which can drastically slow DIPG cell growth in vitro. Some current literature examples of HDAC inhibitors with promising in vitro efficacy are panobinostat and vorinostat. However, these drugs have low in vivo efficacy due to poor BBB-permeability. DIPG research may vastly benefit from the development of lipophilic alternatives to current drugs. These alternatives are hypothesized to retain the in vitro efficacy of present inhibitors while improving BBB-permeability and in vivo efficacy. The proposed project will focus on the chemical design, development, and validation of synthetic pathways for novel anti-DIPG pharmaceuticals. As such, building off the current knowledge of HDAC inhibition can provide a greater understanding of DIPG pathophysiology and potential treatment options.
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
572955
Name
Nafea Yossef
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of Novel Histone Deacetylase Inhibitors for Treatment of Diffuse Intrinsic Pontine Glioma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Chemotherapy; Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma; Dipg; Dmg; Drug Discovery; Medicinal Chemistry; Organic Synthesis
Abstract
Diffuse Intrinsic Pontine Glioma (DIPG) is a highly aggressive pediatric brainstem tumor that affects about 30 Canadian children per year. DIPG tumors cannot be surgically removed as they affect the pons region of the brainstem, which is responsible for many vital functions like heart rate and breathing rate. There are currently no viable chemotherapeutics for DIPG as all drugs that have shown promise in vitro have poor blood-brain barrier (BBB) permeability and off-target toxicity. As such, DIPG has no effective treatment and is universally fatal. The proposed research aims to develop a medicinal chemistry approach to synthesize novel anti-DIPG pharmaceuticals. Current research has shown that DIPG is driven by mutations in histone proteins that cause profound changes in gene transcription patterns, including inhibition of tumor suppressor genes and relative overexpression of oncogenes. This dysregulation of gene expression can be reversed by inhibiting histone deacetylase enzymes (HDACs), which can drastically slow DIPG cell growth in vitro. Some current literature examples of HDAC inhibitors with promising in vitro efficacy are panobinostat and vorinostat. However, these drugs have low in vivo efficacy due to poor BBB-permeability. DIPG research may vastly benefit from the development of lipophilic alternatives to current drugs. These alternatives are hypothesized to retain the in vitro efficacy of present inhibitors while improving BBB-permeability and in vivo efficacy. The proposed project will focus on the chemical design, development, and validation of synthetic pathways for novel anti-DIPG pharmaceuticals. As such, building off the current knowledge of HDAC inhibition can provide a greater understanding of DIPG pathophysiology and potential treatment options.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Nafea, Yossef
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~